BR112015022070A2 - métodos para tratar, reduzir a incidência de, e/ou prevenir eventos isquêmicos - Google Patents

métodos para tratar, reduzir a incidência de, e/ou prevenir eventos isquêmicos

Info

Publication number
BR112015022070A2
BR112015022070A2 BR112015022070A BR112015022070A BR112015022070A2 BR 112015022070 A2 BR112015022070 A2 BR 112015022070A2 BR 112015022070 A BR112015022070 A BR 112015022070A BR 112015022070 A BR112015022070 A BR 112015022070A BR 112015022070 A2 BR112015022070 A2 BR 112015022070A2
Authority
BR
Brazil
Prior art keywords
incidence
treating
reducing
preventing
ischemic event
Prior art date
Application number
BR112015022070A
Other languages
English (en)
Other versions
BR112015022070B1 (pt
Inventor
Arthur Arculus-Meanwell Clive
j schneider David
Prats Jayne
Skerjanec Simona
Original Assignee
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/792,056 external-priority patent/US9427448B2/en
Application filed by The Medicines Co filed Critical The Medicines Co
Publication of BR112015022070A2 publication Critical patent/BR112015022070A2/pt
Publication of BR112015022070B1 publication Critical patent/BR112015022070B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

abstract methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (pci), comprising administering to the patient a pharmaceutical composition comprising cangrelor. the method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a p2y12 inhibitor. pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing pci. the pharmaceutical compositions comprise cangrelor. methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing pci, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. an ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality. tradução do resumo resumo patente de invenção: "métodos para tratar, reduzir a incidência de, e/ou prevenir eventos isquêmicos". trata-se de métodos para tratar, reduzir a incidência de, e/ou prevenir um evento isquêmico em um paciente que é submetido à intervenção coronária percutânea (pci), que compreendem administrar ao paciente uma composição farmacêutica que compreende cangrelor. o método pode compreender, adicionalmente, administrar um agente terapêutico adicional ao paciente, sendo que o agente terapêutico adicional compreende um inibidor de p2y12. as composições farmacêuticas úteis para tratar, reduzir a incidência de, e/ou prevenir um evento isquêmico em um paciente que é submetido à pci. as composições farmacêuticas compreendem cangrelor. os métodos para preparar uma composição farmacêutica para tratar, reduzir a incidência de, e/ou prevenir um evento isquêmico em um paciente que é submetido à pci, que compreendem misturar por adição o cangrelor com um ou mais excipientes farmaceuticamente aceitáveis. um evento isquêmico pode incluir trombose de stent, infarto do miocárdio, revascularização conduzida por isquemia e mortalidade. 1/1
BR112015022070-3A 2013-03-09 2013-05-29 Uso de cangrelor BR112015022070B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/792,056 2013-03-09
US13/792,056 US9427448B2 (en) 2009-11-11 2013-03-09 Methods of treating, reducing the incidence of, and/or preventing ischemic events
US201361815735P 2013-04-25 2013-04-25
US61/815,735 2013-04-25
PCT/US2013/043136 WO2014143107A1 (en) 2013-03-09 2013-05-29 Methods of treating, reducing the incidence of, and/or preventing ischemic events

Publications (2)

Publication Number Publication Date
BR112015022070A2 true BR112015022070A2 (pt) 2017-07-18
BR112015022070B1 BR112015022070B1 (pt) 2022-01-18

Family

ID=51537409

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022070-3A BR112015022070B1 (pt) 2013-03-09 2013-05-29 Uso de cangrelor

Country Status (10)

Country Link
EP (2) EP3978002A1 (pt)
JP (3) JP6247708B2 (pt)
CN (2) CN106102750A (pt)
AU (1) AU2013381855B2 (pt)
BR (1) BR112015022070B1 (pt)
CA (1) CA2904523C (pt)
EA (1) EA034550B1 (pt)
ES (1) ES2904256T3 (pt)
PL (1) PL2964233T3 (pt)
WO (1) WO2014143107A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200018481A (ko) * 2017-06-23 2020-02-19 키에시 파르마슈티시 엣스. 피. 에이. 체폐동맥 션트 혈전증의 예방 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221501B (en) 1993-02-10 2002-10-28 Astrazeneca Ab N-alkyl-2-substituted atp analogues
ID21635A (id) 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
WO2009140092A1 (en) * 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20100297675A1 (en) * 2008-11-24 2010-11-25 Huayun Deng Substrate and method for culturing breast cells
PL2498731T3 (pl) * 2009-11-11 2020-07-13 Chiesi Farmaceutici S.P.A. Sposoby leczenia lub zapobiegania zakrzepicy w stencie

Also Published As

Publication number Publication date
CN106102750A (zh) 2016-11-09
CN115120606A (zh) 2022-09-30
EP2964233B1 (en) 2021-12-15
CA2904523A1 (en) 2014-09-18
EP3978002A1 (en) 2022-04-06
CA2904523C (en) 2024-01-09
ES2904256T3 (es) 2022-04-04
EA034550B1 (ru) 2020-02-19
JP6840197B2 (ja) 2021-03-10
AU2013381855A1 (en) 2015-10-22
EP2964233A1 (en) 2016-01-13
EA201591683A1 (ru) 2016-08-31
PL2964233T3 (pl) 2022-04-25
WO2014143107A1 (en) 2014-09-18
JP2016510738A (ja) 2016-04-11
JP6247708B2 (ja) 2017-12-13
BR112015022070B1 (pt) 2022-01-18
EP2964233A4 (en) 2016-10-19
AU2013381855B2 (en) 2018-08-02
JP2018002739A (ja) 2018-01-11
JP2019178177A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
BR112020015688A8 (pt) Formulações tópicas que compreendem tofacitinibe
BR102016017090B8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
JP2014505733A5 (pt)
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
MY166228A (en) Compositions comprising mixtures of semifluorinated alkanes
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112017026746A2 (pt) composições de liberação de fármacos implantáveis e métodos de uso dos mesmos
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
BR112014028643A8 (pt) Profármaco de alta penetração, seus usos, e composição farmacêutica
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112014027884A2 (pt) combinações farmacêuticas para tratamento de distúrbios metabólicos
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112019022307A2 (pt) Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza.
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
BR112019024750A2 (pt) uso de glutamina sintetase no tratamento da hiperamonemia
BR112015022070A2 (pt) métodos para tratar, reduzir a incidência de, e/ou prevenir eventos isquêmicos
BR112015009504A2 (pt) inibidores de rock
BR112015024897A2 (pt) derivado de fenila

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: CHIESI FARMACEUTICI S.P.A. (IT)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2013, OBSERVADAS AS CONDICOES LEGAIS.